MGX
Income statement / Annual
Last year (2025), Metagenomi Therapeutics Inc.'s total revenue was $25.21 M,
a decrease of 51.79% from the previous year.
In 2025, Metagenomi Therapeutics Inc.'s net income was -$87.87 M.
See Metagenomi Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$25.21 M |
$52.30 M |
$44.76 M |
$17.20 M |
$243.00 K |
| Cost of Revenue |
$5.32 M
|
$0.00
|
$94.40 M
|
$1.73 M
|
$387.00 K
|
| Gross Profit |
$19.89 M
|
$52.30 M
|
-$49.65 M
|
$15.47 M
|
-$144.00 K
|
| Gross Profit Ratio |
0.79
|
1
|
-1.11
|
0.9
|
-0.59
|
| Research and Development Expenses |
$94.43 M
|
$109.18 M
|
$94.40 M
|
$43.14 M
|
$14.48 M
|
| General & Administrative Expenses |
$26.79 M
|
$32.02 M
|
$28.85 M
|
$18.70 M
|
$9.71 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$26.79 M
|
$32.02 M
|
$28.85 M
|
$18.70 M
|
$9.71 M
|
| Other Expenses |
-$5.32 M
|
$0.00
|
-$94.40 M
|
-$1.73 M
|
-$387.00 K
|
| Operating Expenses |
$115.91 M
|
$141.20 M
|
$28.85 M
|
$60.11 M
|
$23.80 M
|
| Cost And Expenses |
$121.22 M
|
$141.20 M
|
$123.25 M
|
$61.84 M
|
$24.19 M
|
| Interest Income |
$9.47 M
|
$14.72 M
|
$15.47 M
|
$3.42 M
|
$43.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$98.00 K
|
$302.00 K
|
| Depreciation & Amortization |
$5.32 M
|
$5.41 M
|
$4.21 M
|
$1.73 M
|
$387.00 K
|
| EBITDA |
-$82.61 M |
-$78.16 M |
-$56.02 M |
-$39.19 M |
-$20.75 M |
| EBITDA Ratio |
-3.28
|
-1.49
|
-1.25
|
-2.28
|
-85.4
|
| Operating Income Ratio |
-3.81
|
-1.7
|
-1.75
|
-2.6
|
-98.55
|
| Total Other Income/Expenses Net |
$8.09 M
|
$5.33 M
|
$18.26 M
|
$3.62 M
|
$2.51 M
|
| Income Before Tax |
-$87.93 M
|
-$83.57 M
|
-$60.23 M
|
-$41.02 M
|
-$21.44 M
|
| Income Before Tax Ratio |
-3.49
|
-1.6
|
-1.35
|
-2.39
|
-88.24
|
| Income Tax Expense |
-$58.00 K
|
-$5.51 M
|
$8.03 M
|
$2.57 M
|
$0.00
|
| Net Income |
-$87.87 M
|
-$78.06 M
|
-$68.26 M
|
-$43.59 M
|
-$21.44 M
|
| Net Income Ratio |
-3.49
|
-1.49
|
-1.53
|
-2.53
|
-88.24
|
| EPS |
-2.36 |
-2.09 |
-1.82 |
-1.16 |
-3.62 |
| EPS Diluted |
-2.36 |
-2.09 |
-1.82 |
-1.16 |
-3.62 |
| Weighted Average Shares Out |
$37.25 M
|
$37.42 M
|
$37.47 M
|
$37.47 M
|
$5.93 M
|
| Weighted Average Shares Out Diluted |
$37.25 M
|
$37.42 M
|
$37.47 M
|
$37.47 M
|
$5.93 M
|
| Link |
|
|
|
|
|
